# COMPASS Pathways FDA Valuation

> COMPASS Pathways valued at 0.57x Spravato sales with FDA fast-track approval expected.
- Title: COMPASS Pathways FDA Valuation · Seekingalpha | Shortify
- Summary: COMPASS Pathways valued at 0.57x Spravato sales with FDA fast-track approval expected. COMPASS Pathways' stock is valued at 0.57x Spravato's annual sales…
- Keywords: compass pathways, spravato, fda, treatment-resistant depression, phase 3 trials, fast-track approval, money, business, COMPASS, Pathways, Valuation, Seekingalpha
- Source: Seekingalpha — https://seekingalpha.com/article/4955896-compass-pathways-built-the-fdas-way-valued-at-0-57x-spravatos-sales
- Author: Gary Aquilina
- Published: 2026-10-21T14:17:28+00:00
- Read time: 1 min
- Topics: compass pathways, spravato, fda, treatment-resistant depression, phase 3 trials, fast-track approval, money, business
## FDA Fast-Track Approval
COMPASS Pathways' COMP360 trial design matched FDA guidance and achieved statistically significant efficacy similar to Spravato.
## Valuation at 0.57x Sales
COMPASS Pathways holds $433.3 million cash, valued at 0.57x Spravato's annual sales for treatment-resistant depression.
## FDA Review Timeline
COMP360's NDA is expected for a fast-track FDA decision this quarter with potential delays if the NDA slips past Q4.
## Key takeaway

COMPASS Pathways' stock is valued at 0.57x Spravato's annual sales after Phase 3 trials matched FDA guidance for treatment-resistant depression.